Sema4, a health information company, will use screening and diagnostic tests and predictive models to help patients, clinicians and researchers predict health trajectories. The company’s focus will include genetic tests developed at Mount Sinai, such as Sema4 Expanded Carrier Screen, which tests for 281 genetic diseases.
Sema4 will comprise a staff of more than 300, including clinicians, engineers and genetic counselors. Eric Schadt, PhD, dean for precision medicine at the Icahn School of Medicine, will serve as CEO.
“We will incorporate patient information — including genetic, environmental, clinical, pharmaceutical and device data — to model the complexity of disease and wellness and to generate more personalized, precise and real-time insights for our patients,” Dr. Schadt said.
More articles on health IT:
IBM brings Watson for Oncology to China
North Dakota health dept. notifies 2.5k Medicaid patients of privacy breach: 5 things to know
OIG: Top HHS management challenges include information security, data integrity
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
